Veloxity Labs, LLC ads

Enterprise programs need decision-quality bioanalysis on predictable timelines — without endless method cycles or matrix surprises. Veloxity Labs is the first bioanalytical CRO to add the SCIEX ZenoTOF 8600 system to a mature LC–MS/MS (triple-quad) stack, bringing HRAM selectivity and an expanded mass range that supports intact peptides/proteins, interference resolution in complex matrices and small-volume sensitivity for modern clinical designs. What this unlocks for Phase 1–3 and GLP-enabling work: >> Faster method development & troubleshooting for peptides (incl. GLP-1 RAs) and proteins >> Intact mass confirmation + cleaner spectra for confident decisions >> Continuity across phases with ICH M10-aligned, GLP/GCP-aware documentation >> Capacity & scalability: lab expansion + cloud Watson LIMS + automation (VELO™) If peptide or complex modality bioanalysis is on your roadmap, let’s discuss how HRAM + triple-quad together can de-risk timelines — from candidate selection to dose escalation.

Enterprise programs need predictable decisions on schedule—with traceability and documentation that stand up across sites and phases. Co-authored with industry veteran, Andy Vick, PhD, BlueWater Biosciences, our new report, Accelerating Drug Development Along the Entire Lifecycle, outlines a playbook for LC–MS/MS that: • Aligns methods to GLP/GCP and ICH M10 from day one • Structures BioA → PK handoffs so analysis starts immediately • Uses automation (LIMS, standardized templates) to reduce manual steps and transcription risk • Sets clear partner metrics (quote speed, start lead time, QC turnaround) to protect Last Patient/Last Visit and Database Lock timelines Want a brief walk-through for your team? DM us and we’ll set it up. #Pharma #ClinicalOperations #DataIntegrity #LCMS

Sensitive semaglutide quantitation. Straightforward sample preparation. New peer-reviewed research from Veloxity Labs demonstrates a fully validated HPLC-MS/MS method for quantifying semaglutide in human plasma. With a validated calibration range of 5–200 ng/mL, high analyte recovery and minimal matrix effects, the study highlights an analytical approach for supporting GLP-1 drug development. #Bioanalysis #GLP1 #Semaglutide #LCMSMS

Breakthrough therapeutics require close collaboration between platform innovators and scientific partners. Our work with Toralgen demonstrates how integrated bioanalytical expertise can accelerate development decisions and strengthen future partnering opportunities. Developing complex peptides, oral biologics or novel drug delivery technologies? We'd welcome the opportunity to discuss how Veloxity can help generate the data needed to support your next milestone. #ScientificPartnership #Bioanalysis #DrugDevelopment #OralBiologics

Novel oral delivery platforms have the potential to extend beyond today's GLP-1 therapies. From peptides to proteins and other complex biologics, the scientific data generated today will help shape tomorrow's therapeutic landscape. Learn how Veloxity Labs supported validation through specialized bioanalysis for Toralgen's novel oral biologics platform. Advancing the next generation of peptide or biologic therapeutics? Let's discuss how specialized bioanalytical expertise can help accelerate your development program. #GLP1 #OralBiologics #PeptideTherapeutics #DrugDelivery

The future of biologics extends beyond individual molecules. Platform technologies capable of supporting multiple peptide classes have the potential to reshape development strategies, manufacturing and patient access. Learn how Veloxity Labs partnered with Toralgen to support one such platform through specialized bioanalytical expertise. Working on an innovative therapeutic platform? Let's discuss how Veloxity can support your program through rapid method development, advanced LC-MS bioanalysis and pharmacokinetic expertise. #PlatformTechnologies #OralBiologics #BiotechInnovation #Bioanalysis